China’s ABclonal bags $189m in Series D funding co-led by Sequoia Capital China

China’s ABclonal bags $189m in Series D funding co-led by Sequoia Capital China

Life Science

ABclonal Technology, a provider of reagents used in life science research, has raked in 1.2 billion yuan ($189 million) in a Series D round of financing, the investee announced on Wednesday.